ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that ...
Pipeline
ImmuPharma is a biopharmaceutical company that specialises in the usage and development of biopolymers, specifically peptides.
Our late-stage to preclinical pipeline is focused on two core therapeutic areas; autoimmunity & inflammation and anti-infectives.
*Phase 2/3 adaptive trial becomes a pivotal trial for filing
Our core therapeutic areas
The P140 platform
LUPUZORTM for Lupus
P140 for CIDP
BioAMB
for systemic fungal infections
BioCIN
for severe bacterial infections
Key progress
Financial, Business and Portfolio Development Update
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...